In Focus: scaling up and out

The cell and gene therapy industry has undergone remarkable advances in the last decade, bringing life-saving treatments to patients with diseases that were originally thought to be incurable. Growing exponentially, the industry faces challenges in scalability, automation, cell type flexibility and time-to-market and production costs. How can the industry band together to tackle these concerns and achieve the common goal of increasing patient access? 

In this In Focus feature, which has been produced in association with Corning (MA, USA), we’ll be reviewing the technological innovations improving efficiency in cell and gene therapy production, while experts at Cellipont Bioservices (CA, USA) share their experiences of scaling up and out. 


Infographic

How current and new technologies can overcome challenges in adherent scale-upHow can researchers, manufacturers, life science companies and academics work together to improve patient access through scalability? In this infographic, created by RegMedNet in association with Corning (NY, USA), we deep dive into some of the technological innovations enabling efficient scale-up strategies in cell and gene therapy.  

 

Interview

The cost and practicality of scaling up and out: an interview with Mike O’MaraHow can automation increase efficiency in therapeutics? In this interview, Mike O’Mara, Chief Operating Officer of Cellipont Bioservices (CA, USA), discusses the factors affecting cost and practicability of scaling up and out. With over 30 years of experience in manufacturing, supply-chain, quality assurance and quality control, Mike sheds light on the benefits of knowledge-sharing with experienced partners.  

 

Resources 

Exploring what’s possible with stem cell therapies

 

 

 


 

In association with